HDAC9 and neoplasm: Entinostat (ENT; Class I HDAC inhibitor) has shown significant efficacy in tumor immunotherapy when combined with anti-PD-1/anti-CTLA-4 antibodies, functioning by reducing the number of tumor-infiltrating G-MDSCs (257).